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Recent analyses based on UK data indicate that people who stop smoking, even well into middle age, avoid most of their subsequent
risk of lung cancer. We investigated whether similar absolute risks of lung cancer in men are found in other European countries with
different smoking patterns and at different stages of their lung cancer epidemic. Using data for men from a multicentre case–control
study of lung cancer in the UK, Germany, Italy and Sweden, and including 6523 lung cancer cases and 9468 controls, we combined
odds ratio estimates with estimates of national lung cancer incidence rates to calculate the cumulative risk of lung cancer among men
by age 75. Lung cancer cumulative risks by age 75 among continuing smokers were similar for the UK, Germany and Italy at 15.7, 14.3
and 13.8% respectively, whereas the cumulative risk among Swedish male smokers was 6.6%. The proportion of the risk of lung
cancer avoided by quitting smoking before the age of 40 was comparable between the four countries, at 80% in Italy and 91% in the
UK, Germany and Sweden. Similarly, the proportion of the excess risk avoided by quitting before the age of 50 ranged from 57% in
Italy to 69% in Germany. Our results support the important conclusion that for long-term smokers, giving up smoking in middle age
avoids most of the subsequent risk of lung cancer, and that lung cancer mortality in European men over the next three decades will
be determined by the extent to which current smokers can successfully quit smoking.
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Smoking of tobacco products, and in particular of cigarettes, is
responsible for most cases of lung cancer in Europe and North
America, with an attributable proportion among men in the order
of 90% (Peto et al, 1992; Mannino et al, 2001; Simonato et al, 2001;
Jemal et al, 2003). The association between lung cancer and
cigarette smoking is strongly related to duration of smoking, and
to a lesser extent the amount of tobacco smoked per day, the type
of cigarette and other characteristics such as inhalation patterns
(Lubin et al, 1984; Boffetta et al, 1999). Measuring precisely the
absolute risk of lung cancer for various patterns of smoking (e.g.
heavy smokers, long-term ex-smokers) typically requires informa-
tion on large cohorts with long-term follow-up information. A
more efficient, although rarely used, approach (Cornfield, 1951) is
to combine measures of odds ratio (OR) from case–control studies
with relevant incidence or mortality data. A recent example was
based on a case–control study of lung cancer in southwest
England including 667 male cases and 2108 male controls (Peto
et al, 2000). By incorporating national UK mortality rates for lung
cancer in males, the cumulative risk of death from lung cancer by
age 75 among current smokers was estimated at 16%, rising to 24%
for current smokers of at least 25 cigarettes per day. The benefit of
quitting smoking was demonstrated with cumulative risks of lung
cancer of 10, 6, 3 and 2% for men who stopped smoking at ages 60,
50, 40 and 30, respectively. It is therefore apparent that smokers
who quit, even well into middle age, avoid a large proportion of
their subsequent risk of lung cancer. Using a larger multicentre
case–control study of lung cancer in Europe, which included the
above UK data (Simonato et al, 2001), we investigated whether the
absolute risks of lung cancer in men are similar in other European
countries with different smoking patterns and in different stages of
the lung cancer epidemic.
MATERIALS AND METHODS
The analysis was based on a multicentre case–control study of
lung cancer among men conducted from 1985 to 1994 in the UK,
Germany, Italy and Sweden (Jo ¨ckel et al, 1998; Nyberg et al, 2000;
Peto et al, 2000; Kreienbrock et al, 2001; Fortes et al, 2003; Kreuzer
et al, 2003; Richiardi et al, 2004). The UK data formed the basis of
the previous absolute risk analysis (Peto et al, 2000). Three centres
were in Germany, three in Italy and one each in Sweden and the
UK (Table 1). Cases were incident patients with lung cancer aged
below 75 years and, for Germany, Italy and Sweden, histologically
or cytologically confirmed. Controls were a random sample of the
underlying populations selected from local population registers,
with the exception of Centre III in Italy, in which controls were
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for a disease unrelated to smoking. In the UK, a separate hospital
control group was also recruited using criteria similar to those in
the Italian study. In Sweden, besides the population controls in
Stockholm, a second group of mortality-matched controls was
selected from among those who died in the same year as the cases
but from a nontobacco-related cause of death. For both Sweden
and the UK, the distribution of the smoking habits in the two
control groups was similar and the results are presented here with
the two groups combined.
All subjects who had regularly smoked at least one cigarette per
day for at least 1 year (6 months in Germany) were considered
current or ex-smokers. Current smokers were those who still
smoked at interview or had quit less than 2 years previously (1
year in the UK), while ex-smokers were those who had quit 2 or 3
years previously. When information on different time periods was
available for current smokers, the most recent number of cigarettes
smoked was used. Information on other tobacco smoking products
was also included after weighting for the amount of tobacco (one
pipe¼one cigar¼1.5 cigarillos¼3 cigarettes). Smokers of only
cigars or pipes were excluded from the analysis in the UK data set.
Country-specific relative risks of lung cancer were estimated by
means of OR with 95% confidence intervals using unconditional
logistic regression (Breslow and Day, 1980) and adjusting for age.
Smoking categories were introduced as dummy variables, and ORs
were estimated for each smoking category compared to never-
smokers. Overall results for Germany and Italy were calculated by
pooling the data from the three centres in each country and
adjusting by centre.
The absolute risks were estimated by combining the male age-
specific cancer incidence rate in each country with OR for the
different smoking categories and the age-specific prevalence of the
different smoking habits among study controls (see Appendix A1
for further details). Our assumption was that within each age
group the smoking distribution of each national population was
represented by our control distribution. Finally, we calculated the
cumulative rate (C) for the different categories of smoker by
adding age-specific absolute rates (in 5-year age groups), and then
the cumulative risk by age 75 using the standard formula
(1 exp( 5C/10
5)) (Breslow and Day, 1987). The cumulative risk
may be interpreted as the probability that an individual will
develop lung cancer before the age of 75 in the absence of
competing causes of death.
National lung cancer incidence rates for the period 1988–1992
were used for the UK and Sweden (Parkin et al, 2003). As national
lung cancer incidence rates are not available for Germany and
Italy, we estimated these by using the age-specific national lung
cancer mortality data corrected by survival rates to obtain an
adjusted incidence rate:
incidence rate ¼ð national mortality rate=ð1   relative survival
rateÞÞ
Age-specific lung cancer mortality rates were averaged over the
period 1988–1994, covering the period when most subjects were
recruited. Country-specific lung cancer relative survival data
(adjusted for competing causes of death) were obtained from the
EUROCARE study (Janssen-Heijnen et al, 1998) covering the
period 1985–1994.
95% confidence intervals for cumulative risks were calculated
using floating absolute risks to obtain the variance of the logarithm
of OR Var(logr) (Easton et al, 1991) and subsequently incorporat-
ing a Taylor series expansion. The method of floating absolute
risks leads to confidence intervals that are approximately
independent and are therefore readily interpreted (Plummer,
2004). Sampling variations in smoking prevalence estimates are
not included in the calculation of the confidence intervals,
resulting in intervals that may be somewhat too narrow. Further
details are given in Appendix A1.
RESULTS
A total of 6523 cases and 9468 controls have been included in the
analysis. The ORs associated with cigarette smoking are presented
in Table 2, those for current and ex-smokers being higher in the
UK than in the other countries, although this is based on very few
(three) lifelong nonsmoking cases in the UK. Cumulative risks for
Table 1 Distribution of the study subjects by centre and case–control status
Centre Reference
a Case/control Region Source of cases Source of controls
UK Peto et al (2000) 667/2108 Southwest England Residents in Devon and
Cornwall
Population registers and
patients from hospitals of cases
Germany Population registers and
random digit dialling
Total 3464/3501
Germany I Jo ¨ckel et al (1998) 805/799 (I) Bremen, Frankfurt (I) Residents in Bremen,
Frankfurt metropolitan areas
Germany II Kreienbrock et al (2001) 1850/1796 (II) Parts of Northrhine-
Westfalia, Rhineland-Palatine,
Saarland, Eastern Bavaria
(II) Residents in parts of
Northrhine-Westfalia,
Rhineland-Palatine, Saarland,
Eastern Bavaria
Germany III Kreuzer et al (2003) 809/906 (III) Thuringia and Saxony (III) Residents in Thuringia and
Saxony
Italy Population registers and
patients from hospital of cases
Total 1377/1535
Italy I Richiardi et al (2004) 538/684 (I) Turin (I) Residents in Turin
Italy II Richiardi et al (2004) 510/582 (II) Veneto region (II) Five areas of Veneto region
Italy III Fortes et al (2003) 329/269 (III) Rome (III) Patients from one hospital
in Rome
Sweden Nyberg et al (2000) 1015/2324 Stockholm county Residents in Stockholm county Population registers
aNumber of subjects included in pooled analysis do not correspond exactly with numbers of subjects in original publications.
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ranging from 0.2% in the UK to 0.6% in Italy and Germany.
Cumulative risks among ex–smokers were 4.2% in Germany, 5.7%
in the UK and 6.5% in Italy, while in current smokers they were
14.3% in Germany, 15.7% in the UK and 13.8% in Italy. In Sweden,
however, these cumulative risks were somewhat lower at 2.3% for
ex-smokers and 6.6% for current smokers.
In Table 3, cumulative risks among ex-smokers are presented
after stratifying for age at quitting. For the UK, the cumulative risk
of lung cancer by age 75 was 11.1, 5.6 and 2.6% among men who
stopped at around 60, 50 and 40 years of age, respectively. For
Germany and Italy, the cumulative risks of lung cancer by age 75
among ex-smokers were similar to those obtained for the UK. For
Sweden, the cumulative risk by age 75 was 4.2, 2.1 and 0.8%
for those who stopped at around 60, 50 and 40 years of age.
These results are presented in further detail in Figure 1, which
includes the age-specific cumulative risk in each category of
smoking.
The cumulative risks for current smokers according to the
number of cigarettes currently smoked per day are presented in
Table 4. Among heavy smokers (25þ per day), risks were similar
in the UK, Germany and Italy at 23.6, 25.7 and 20.1% respectively,
while in Sweden they were much lower at 12.6%. The pattern
among moderate smokers (15–24 per day) was much the same as
for heavy smokers, although risks were somewhat lower. For light
smokers (o5 per day), risks were similar in Germany and Italy at
2.5 and 1.8, although were higher in the UK and Sweden. This is
probably due to the larger amount of cigarettes these ‘light’
smokers had smoked in the past. For example, over 90% of the
lung cancer cases in the UK who were classified as light smokers
had previously smoked over 15 cigarettes per day.
DISCUSSION
The primary aim of the analysis was to determine whether the
absolute risks of developing lung cancer for various groups of
smokers in different European countries are similar to those
previously reported for the UK (Peto et al, 2000). A high degree of
consistency was observed between results for the UK, Germany
and Italy. In all three countries, the cumulative risk of developing
lung cancer by age 75 for continuing smokers was around 14–16%,
or about one in seven, and the risk for continuing heavy smokers
was around 20–25%, or around one in four to one in five. Given
that some of these heavy smokers may have been light smokers
previously, it is possible that the true cumulative risk for those who
have been heavy smokers throughout their adult lives may be even
higher. Finally, the relationship between lung cancer risk and
quitting smoking was very similar in the UK, Germany and Italy.
Overall, the proportion of the excess absolute risk of lung cancer
by age 75 compared to never-smokers that was avoided by quitting
smoking at age 40 was 85, 91 and 80% in the UK, Germany and
Italy respectively. Similarly, the proportion of the excess lung
cancer risk avoided by quitting at age 50 was 65, 69 and 57%,
respectively. A substantially lower cumulative risk was observed in
Sweden, with the lifetime risk of current smokers up to age 75
being approximately half that identified in the other three
countries. However, the proportion of the excess lung cancer risk
avoided by quitting was similar to the other three countries, with
94 and 73% of the excess risk being avoided by those who quit
before age 40 and 50, respectively.
The heterogeneity of the results from Sweden as compared to the
other three countries raises the possibility of bias in our results.
However, there is no obvious reason why the cumulative risk in the
Swedish study was seriously underestimated. The study recruited a
series of incident cases and two control groups, which were
subsequently combined: one a group of population controls
selected among the Stockholm population alive at the end of the
year of recruitment among the cases, and the second a group of
controls frequency-matched to cases on vital status at the end of
the study period. Individuals who had died of a tobacco-related
cause were not included in this second control group (Gustavsson
et al, 2000). The Swedish study was restricted to Stockholm county,
whereas cumulative risks were calculated based on national
incidence rates. We therefore repeated the analysis of the
Swedish data using incidence data from Stockholm county.
The resulting cumulative risks by age 75 in Stockholm County
were 0.4, 2.4 and 6.5% for never-, ex- and current smokers
respectively, which are similar to the figures obtained using
national figures.
Table 2 Odds ratios and cumulative risks of lung cancer by age 75, for never-, ex- and current cigarette smokers, among men, by country
Country Case/control OR
a Standard
a 95% CI Floating
b 95% CI Cumulative risk
c (95% CI)
UK
d
Nonsmoker 3/400 1.0 0.3–3.1 0.2 (0.01–0.4)
Ex-smoker 285/1106 34.4 10.9–107.5 30.2–39.1 5.7 (5.0–6.4)
Current smoker 322/453 94.8 30.2–297.8 82.2–109.3 15.7 (14.4–17.0)
Germany
Nonsmoker 63/763 1.0 0.8–1.3 0.6 (0.4–0.7)
Ex-smoker 1059/1699 7.5 5.7–9.8 7.0–8.1 4.2 (4.0–4.5)
Current smoker 2342/1039 27.3 20.9–35.6 25.4–29.4 14.3 (13.6–15.0)
Italy
Nonsmoker 18/277 1.0 0.6–1.6 0.6 (0.3–0.9)
Ex-smoker 520/716 11.2 6.8–18.2 10.0–12.5 6.5 (5.9–7.0)
Current smoker 833/539 23.7 14.6–38.7 21.3–26.5 13.8 (12.8–14.8)
Sweden
Nonsmoker 36/706 1.0 0.7–1.4 0.4 (0.2–0.5)
Ex-smoker 263/813 6.3 4.4–9.1 5.5–7.3 2.3 (2.0–2.6)
Current smoker 716/805 17.4 12.3–24.7 15.3–19.3 6.6 (6.2–7.0)
aOdds ratios and 95% confidence intervals calculated by logistic regression analyses, adjusted for age and centre.
b95% confidence intervals are based on floating variance.
cCumulative risk expressed as percentage; 95% confidence intervals are based on floating variance.
dUK estimates of cumulative risk differ slightly from those previously reported
(Peto et al, 2000) due to use of incidence instead of mortality data. The OR for ex-smokers and current smokers in UK are also anomalously high by chance, due to the fact that
the number of nonsmokers was unusually low by chance. This anomaly will have a minimal effect on the UK cumulative risks for current and ex-smokers. See text for an
explanation.
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started smoking at a later age than in other countries. We therefore
repeated the calculation of cumulative risk after stratifying for age
at onset of smoking. Among continuing smokers who started
smoking before the age of 16, the cumulative risk of lung cancer by
age 75 was 16.5% in the UK, 20.7% in Germany, 21.7% in Italy and
11.5% in Sweden. Results from such stratified analyses are unstable
due to smaller numbers, although they do not indicate that the
lower cumulative risks observed in Sweden are fully explained by a
later age of onset of smoking. Other possible explanations for the
low cumulative lung cancer risk among Swedish men may be
different inhalation patterns, smoking of a higher proportion of
low-tar cigarettes, and simultaneous use of smokeless tobacco
products resulting in a reduced intensity of smoking (Foulds et al,
2003), although no information was collected on these aspects.
The age-standardised mortality rate for lung cancer among
Swedish males is substantially lower than in other European
countries, at 22.6 per 100000 for the year 2000, while current
mortality rates in the UK (48.6), Germany (46.2) and Italy (52.6)
are more typical of other European countries (Ferlay et al, 2001).
The difference between Sweden and the other countries cannot be
explained by differences in consumption. In 1950, consumption of
manufactured cigarettes per adult per day was 1.8 in Italy and
West Germany, 2.2 in Sweden and 6.0 in the UK (Forey et al, 2002).
Separate figures are not available for men and women, although it
is likely that the vast majority of cigarettes were smoked by men in
all these countries. In Italy and Sweden, consumption subsequently
rose steadily after 1950, reaching 6.3 and 4.5 respectively by 1985.
In West Germany and the UK, consumption increased from 1950
and peaked in the early 1970s at 7.3 and 8.8 respectively, with
subsequent declines to 6.4 and 5.9 respectively by 1985. In all these
countries, the proportion of cigarettes that were smoked by women
increased during the period 1950–1985, although to a lesser extent
in Italy than elsewhere.
The anomalously high ORs for current and ex-smokers for the
UK are attributable to the fact that only three nonsmoking lung
cancer cases were found in this study, corresponding to a
cumulative risk by age 75 of 0.2%. The majority of the evidence
concerning lung cancer risks in lifelong nonsmokers in the UK
indicates that they are similar to those seen in the American
Cancer Society (ACS) prospective study, corresponding to a
cumulative risk by age 75 of around 0.4% (Peto et al, 1992),
suggesting that the low number of nonsmokers observed in the
study was a chance finding. In a previous analysis of data from this
study in which the ACS data were used for nonsmokers, the ratio
of risks in current smokers compared with nonsmokers was
estimated to be 100:3, that is, about 33.3 (Peto et al, 2000). The
same argument would also reduce the ratio of risks in ex-smokers
to nonsmokers by a factor of about three. This would suggest that
the ORs for current and ex-smokers in the UK are in fact quite
compatible with those observed for Germany and Italy.
The anomalously high ORs for the UK have only a minimal
effect on the cumulative risks. The reason for this is that the sum of
the cumulative risks for all three categories of smokers combined
is constrained to be equal to the total cumulative risk as
determined by the absolute rate of lung cancer. As the estimated
cumulative risk among lifelong nonsmokers in the UK is probably
about 0.2% too low, the sum of the cumulative risks for the other
two categories is probably about 0.2% too high. The cumulative
risks for ex-smokers and current smokers in the UK as
given in Table 2 are therefore probably each too high by about
0.1%.
Table 3 Odds ratios and cumulative risks of lung cancer by age 75, by age at quitting smoking, among men, by country
Centres Case/control OR
a Standard
a 95% CI Floating
b 95% CI Cumulative risk
c (95% CI)
UK
d
Nonsmoker 3/400 1.0 0.3–3.1 0.2 (0.01–0.4)
o30 years 6/122 6.6 1.6–26.6 2.9–14.9 1.1 (0.3–1.9)
40 years 12/193 8.3 2.3–29.7 4.6–14.9 2.6 (1.3–3.9)
50 years 44/246 23.8 7.3–77.6 17.3–32.9 5.6 (4.1–7.0)
60 years 223/545 54.6 17.3–171.7 46.7–63.8 11.1 (9.4–12.8)
Current smoker 322/453 94.8 30.2–297.8 82.2–109.3 15.7 (14.4–17.0)
Germany
Nonsmoker 63/763 1.0 0.8–1.3 0.6 (0.4–0.7)
o30 years 27/294 1.03 0.6–1.6 0.7–1.5 0.6 (0.3–0.8)
40 years 52/426 2.8 1.9–3.9 2.2–3.5 1.8 (1.4–2.1)
50 years 169/498 6.8 5.0–9.1 5.9–7.9 4.9 (4.4–5.4)
60 years 804/481 15.0 11.2–20.1 13.0–17.3 10.8 (10.0–11.6)
Current smoker 2342/1039 27.3 20.9–35.6 25.4–29.4 14.3 (13.6–15.0)
Italy
Nonsmoker 18/277 1.0 0.6–1.6 0.6 (0.3–0.9)
o30 years 34/103 5.6 2.9–10.6 3.6–8.6 3.4 (2.0–4.9)
40 years 61/131 4.9 2.7–9.0 3.4–7.2 3.3 (2.1–4.4)
50 years 130/268 8.9 5.2–15.1 7.0–11.3 6.3 (5.1–7.5)
60 years 295/214 12.7 7.6–21.2 10.5–15.4 10.2 (9.1–11.2)
Current smoker 833/539 23.7 14.6–38.7 21.3–26.5 13.8 (12.8–14.8)
Sweden
Nonsmoker 36/706 1.0 0.7–1.4 0.4 (0.2–0.5)
o30 years 4/71 1.1 0.4–3.2 0.4–3.0 0.4 (0.01–0.8)
40 years 14/158 1.7 0.9–3.3 1.0–3.0 0.8 (0.4–1.1)
50 years 46/215 4.2 2.6–6.6 3.1–5.8 2.1 (1.6–2.6)
60 years 199/369 7.2 4.7–10.9 5.7–9.3 4.2 (3.6–4.8)
Current smoker 716/805 17.4 12.3–24.7 15.3–19.3 6.6 (6.2–7.0)
aOdds ratio and 95% confidence intervals calculated by logistic regression analyses, adjusted for age and centre.
b95% confidence intervals are based on floating variance.
cCumulative risk expressed as percentage; 95% confidence intervals are based on floating variance.
dSee footnote to Table 2 concerning the anomalously high odds ratios for the
UK study.
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Figure 1 Effects of stopping smoking at various ages on the cumulative risk (%) of death from lung cancer up to age 75 at incidence rate for men in
Europe.
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considering its implications, it is noteworthy that a comparably
large benefit of stopping smoking was found for all-cause mortality
in the prospective study among British doctors (Doll et al, 1994).
In a recent review of smoking-related mortality in developed
countries (Peto et al, 2003), it has been estimated that during the
year 2000 in the 15 countries, then members of the European
Union, there were 172000 smoking-attributed male deaths
at ages 35–69, comprising 29% of all male deaths in this age
range, while for all ages the corresponding figures were 398000
and 22%. In the 10 new member states of the European Union,
the proportion of deaths attributable to smoking is even higher.
It is estimated that, in 2000, 37% of all male deaths at ages 35–69
and 28% of all male deaths were attributable to smoking,
corresponding to 73000 deaths at ages 35–39 and 113000 at
all ages. The estimates of cumulative risk obtained in the present
study reinforce the conclusion that, for people who have
been smoking for many years, giving up smoking in middle age
means avoiding most of the subsequent risk of developing lung
cancer or of dying from a tobacco-related disease. This result has
major public health implications. Tobacco-related mortality in
Europe over the next three decades will be determined by the
extent to which current smokers can be persuaded to quit
smoking.
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5–14day 1 108/179 80.9 25.2–256.7 63.3–102.1 13.1 (11.2–16.0)
15–24day
 1 126/169 99.4 31.2–316.7 78.9–125.2 16.5 (13.7–19.2)
25+day
 1 68/61 148.6 45.3–487.0 105.2–210.0 23.6 (17.5–29.3)
Germany
Nonsmoker 63/763 1.0 0.8–1.3 0.6 (0.4–0.7)
o5day
 1 28/91 4.5 2.4–8.4 2.5–8.0 2.5(2.1–3.0)
5–14day
 1 576/412 17.6 13.1–23.6 15.3–20.3 9.5 (9.0–10.1)
15–24day
 1 1171/385 33.6 25.3–44.5 29.9–37.8 17.4 (16.6–18.2)
25+day
 1 567/147 52.2 37.7–73.2 42.8–63.6 25.7 (24.3–27.0)
Italy
Nonsmoker 18/277 1.0 0.6–1.6 0.6 (0.3–0.9)
o5day
 1 10/32 3.0 1.1–8.1 1.2–7.1 1.8 (1.4–2.3)
5–14day
 1 206/202 13.9 8.2–22.4 11.3–17.1 8.3 (7.6–9.0)
15–24day
 1 395/208 26.8 16.1–44.5 22.5–31.9 15.4 (14.4–16.4)
25+day
 1 222/97 35.9 21.0–61.4 28.0–46.0 20.1 (18.6–21.5)
Sweden
Nonsmoker 36/706 1.0 0.7–1.4 0.4 (0.2–0.5)
o5day
 1 14/14 19.6 8.7–44.2 9.3–41.1 7.0 (4.8–9.2)
5–14day
 1 193/346 10.9 7.5–15.9 9.2–13.0 4.0 (3.6–4.3)
15–24day
 1 320/325 19.3 13.3–27.9 16.5–22.5 6.9 (6.5–7.4)
25+day
 1 189/79 36.2 23.5–55.8 27.6–47.7 12.6 (11.3–13.9)
aOdds ratios and 95% confidence intervals calculated by logistic regression analyses, adjusted for age and centre.
b95% confidence intervals are based on floating variance.
cCumulative risk expressed as percentage; 95% confidence intervals are based on floating variance.
dThe cumulative risks for smokers of o5day
 1 are anomalously high in UK. Of
these cases, 93% had smoked over 15day
 1 in the past, and several had smoked over 30.
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Appendix A1
The cumulative risk was calculated using methods similar to those
described by Peto et al (2000). The following box summarises the
main measures used to obtain the cumulative risk:
Briefly, to estimate the cumulative risk, first we need to calculate
the relative risks in the various smoking categories (1). In our
study, the relative risks of lung cancer were estimated by means of
OR using unconditional logistic regression, and lifelong non-
smokers formed the reference category.
The second step was to calculate the percentage of controls in
each smoking category and for each age group (2) using the
assumption that within each country the smoking distribution of
the population was represented by the smoking distribution
observed among the study controls.
The third step was the estimation of common factors combining
the relative risk (1) for the different smoking categories with the
age-specific prevalence of such smoking habits among study
controls (2), thus obtaining the quantities denoted by (3).
Combining the age-specific cancer incidence rates of each
country (4) with the common factors (3), we obtained the
proportions given in (5). Multiplying these proportions with the
relative risks for the different smoking categories produced the
age-specific absolute risks in the different smoking categories (6).
Next we calculated the cumulative rates (7) for the different
categories of smoker by adding age-specific absolute rates, and
then finally the cumulative risks by age 75 were estimated using the
standard formula (8). The cumulative risk may be interpreted as
the probability that an individual will develop lung cancer before
age 75 in the absence of competing causes of death.
ri is the relative risk in the iith smoking category (1)
where the smoking categories are: 1¼never-smokers, 2¼ex-
smokers (subdivided in some analyses by age at which they quit
smoking (o30, 30  40 ,5 0  , 60+), 3¼current smokers
subdivided in some analyses by number of cigarettes per day (o5,
5 14, 15 24, 25+)
pij is the percentage of the controls in the jth age group and the ith
smoking category
(2)
where the age categories are 35–39, 40 44, 45 49, 50 54,
55 59, 60 64, 65 69 and 70 74 years
Sj¼r1p1j+?+ripij (3)
hj is the age-specific incidence rate (4)
fj¼hj/(S1+?+Sj) (5)
aij is the absolute rate in the (i,j)th cell, and aij¼(fjri) (6)
Ci is the cumulative rate, and Ci¼
P
jRjaij (7)
where Rj is the width of the jth age category in years
cumulative risk (%)¼100(1 exp( Ci)) (8)
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